ОбзорГрафикНовости

One-Month SOFR Futures (SR1 Декабрь 2024)/  XFTTSR1CMEGL  /  CME GLOBEX

26.12.2024 22:48:17 Изменение -0.0175 Бид0:00:04 Предложение0:00:04 Открыть Максимум Минимум Предыдущее закрытие
95.4725USD -0.02% 95.4700 95.4750 95.4925 95.4925 95.4650 95.4900
Newsfile Corp 04.11 Sekuya Racing Secures Third Straight Win at Mandalika Festival of Speed 2024
Newsfile Corp 14.10 Sekuya Racing and Neiro Gear Up for Radical Time Attack 2 with Senna Iriawan at Mandalika
GlobeNewswire 18.07 Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resi...
GlobeNewswire 10.06 Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...
GlobeNewswire 06.06 Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Laso...
Newsfile Corp 06.06 First Fence Enhances Property Security with LPS 1175 Rated ProFence(R) SR1 System
GlobeNewswire 30.05 Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire 29.04 Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s...
GlobeNewswire 12.12.2023 Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE La...
GlobeNewswire 12.12.2023 Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient...
GlobeNewswire 06.11.2023 Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete R...
GlobeNewswire 13.12.2021 Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposi...
GlobeNewswire 15.11.2021 Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ve...
GlobeNewswire 16.08.2021 Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessin...
GlobeNewswire 28.06.2021 Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasof...
GlobeNewswire 21.04.2021 Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential ...
GlobeNewswire 03.12.2020 Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Compan...
GlobeNewswire 13.10.2020 Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combin...
GlobeNewswire 30.09.2020 Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canad...
GlobeNewswire 08.07.2020 Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofo...
GlobeNewswire 25.09.2019 Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Meta...
GlobeNewswire 23.09.2019 Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medici...
GlobeNewswire 31.07.2019 Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office
GlobeNewswire 03.06.2019 Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Tr...
GlobeNewswire 28.05.2019 Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene